Investors with an interest in Beverages - Alcohol stocks have likely encountered both Kirin Holdings Co. (KNBWY) and Anheuser-Busch Inbev (BUD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and t ...

PRINCETON, N.J., Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting to be held in Orlando, Florida from March 7-11, 2025.AD, a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus ...

Investors with an interest in Beverages - Alcohol stocks have likely encountered both Kirin Holdings Co. (KNBWY) and Anheuser-Busch Inbev (BUD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revision ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and ...

GUILFORD, Conn., Jan. 28, 2025 (GLOBE NEWSWIRE) -- AlphaMeld Corporation, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and development, today announced the continuation and expansion of its collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin), a Japan-based global specialty pharmaceutical company. The enhanced partnership provides enterprise-wide access to AlphaMeld Corporation’s proprietary AI-powered Al ...

Investors interested in stocks from the Beverages - Alcohol sector have probably already heard of Kirin Holdings Co. (KNBWY) and Diageo (DEO) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision tre ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Collaboration Overview - Kura Oncology and Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib, a selective oral menin inhibitor for treating acute myeloid leukemia (AML) and other hematologic malignancies [1] - Kura will receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments [1][2] - The collaboration includes a 50/50 profit share in the U.S., with Kura leading U.S. development and commercial activities, while Kyowa Kirin has exclusive commercialization rights outside the U.S. [1][3][4] Financial and Commercial Terms - Kura is eligible for additional milestone payments totaling $741 million, bringing the total potential payments to $1.161 billion, including the opt-in for solid tumor indications [2] - In the U.S., Kura will book sales and lead commercial strategy, sharing profits and losses equally with Kyowa Kirin [3][9] - Outside the U.S., Kyowa Kirin will lead commercialization, and Kura will receive tiered double-digit royalties on net product sales [4][9] Development and Clinical Plans - The companies will jointly pursue a broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies, and post-transplant maintenance settings [1][6] - Kura anticipates that the collaboration funding, combined with its current cash balance, will support the AML program through commercialization in frontline combination therapy [1][8] - The companies plan to launch multiple Phase 2 and Phase 3 studies of ziftomenib in AML and other hematologic malignancies over the next several years [10] Regulatory and Market Potential - Ziftomenib has received Breakthrough Therapy Designation from the FDA for the treatment of relapsed/refractory NPM1-mutant AML, a mutation associated with poor outcomes [6][14] - Kura expects to submit a New Drug Application (NDA) in 2025 and initiate registrational Phase 3 frontline studies in both fit and unfit AML patient populations in 2025 [6][8] - The U.S. market opportunity for ziftomenib in the frontline setting is estimated at up to $3 billion annually [8] Additional Collaboration Details - Kura will fund development costs until the end of 2028, after which both companies will share costs at a 50:50 ratio [10] - Kyowa Kirin has an option to participate in the development and commercialization of ziftomenib in gastrointestinal stromal tumors (GIST) and other solid tumor indications, with Kura eligible for additional upfront and milestone payments totaling $228 million if the option is exercised [11] - The collaboration excludes Kura's ongoing efforts to advance next-generation menin inhibitor drug candidates targeting oncology indications, diabetes, and other metabolic diseases [11]

Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get sta ...